As the global economy mends, the 2021 growth of Urinary Tract Infection (UTI) will have significant change from previous year. According to our (LP Information) latest study, the global Urinary Tract Infection (UTI) market size is USD million in 2022 from USD million in 2021, with a change of % between 2021 and 2022. The global Urinary Tract Infection (UTI) market size will reach USD million in 2028, growing at a CAGR of % over the analysis period.
The United States Urinary Tract Infection (UTI) market is expected at value of US$ million in 2021 and grow at approximately % CAGR during review period. China constitutes a % market for the global Urinary Tract Infection (UTI) market, reaching US$ million by the year 2028. As for the Europe Urinary Tract Infection (UTI) landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period. In APAC, the growth rates of other notable markets (Japan and South Korea) are projected to be at % and % respectively for the next 5-year period.
Global main Urinary Tract Infection (UTI) players cover Novartis AG, GlaxoSmithKline, Dr. Reddy’s Laboratories Ltd.,, and Pfizer, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.
This report presents a comprehensive overview, market shares, and growth opportunities of Urinary Tract Infection (UTI) market by product type, application, key players and key regions and countries.
Segmentation by type: breakdown data from 2017 to 2022 in Section 2.3; and forecast to 2028 in section 10.7.
By Site of Infection
Upper Urinary Tract Infection
Lower Urinary Tract Infection
By Clinical Symptoms
Symptomatic Urinary Tract Infection
Asymptomatic Urinary Tract Infection
By Presence of Urinary Tract Abnormalities
Simple/uncomplicated Urinary Tract Infection
Complex Urinary Tract Infection
Segmentation by application: breakdown data from 2017 to 2022, in Section 2.4; and forecast to 2028 in section 10.8.
Hospitals
Clinic
Self-administered
Others
This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the major players in the market. The key players covered in this report: Breakdown data in in Chapter 3.
Novartis AG
GlaxoSmithKline
Dr. Reddy’s Laboratories Ltd.,
Pfizer
Roche
AstraZeneca,
Cipla
Johnson & Johnson
Bayer AG
Teva Pharmaceutical Industries
Boehringer Ingelheim
Sanofi
Lily
Abbott
JinShuiBao
Shanghai Sine Pharmaceutical Laboratories (Shanghai Pharmaceuticals Holding)
Sinopharm
Borui Medicine
Zhejiang Xianju Pharmaceutical
Sichuan Guorui Pharmaceutical
Hengrui Pharmaceutical